Skip to main content

Advertisement

SpringerLink
Log in

Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Non-small cell lung cancer (NSCLC) is considered potentially curable by multimodal therapy in a subset of patients, including those with locally advanced (LA) disease or nodal spread, who would otherwise have a poor prognosis. Guidelines recommend perioperative chemotherapy with platinum-based regimens, with or without radiotherapy, as the standard treatment modality for high-risk resectable LA-NSCLC. Although the classical regimens of adjuvant chemotherapy have been platinum-based doublet or oral agents such as tegafur/uracil, some molecular targeted therapeutic agents and immune checkpoint inhibitors have been developed recently with an expected favorable effect. Recent trials of perioperative therapy using these agents have demonstrated favourable anticancer efficacy for LA-NSCLC with an acceptable adverse events profile. The ideal timing of perioperative therapy administration, before or after surgery, is still controversial. Because some speculation and concepts have arisen from basic research, several trials are ongoing to clarify the efficacy of newly developed agents in the adjuvant or neoadjuvant setting. This review discusses the role of surgery in the new era and analyzes when and which optimal perioperative multimodal therapy, including chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy, should be administered for resectable or potentially resectable NSCLC to provide possible complete cure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kris MG, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, et al. Making checkpoint inhibitors part of treatment of patients with locally advanced lung cancers: the time is now. Am Soc Clin Oncol Educ Book. 2020;40:1–12.

    PubMed  PubMed Central  Google Scholar 

  2. Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786–95.

    Article  CAS  Google Scholar 

  3. Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: phase III, double-blind, randomized study of osimertinib versus PBO in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer. 2018;19:e533–6.

    Article  CAS  Google Scholar 

  4. Casiraghi M, Bertolaccini L, Sedda G, Petrella F, Galetta D, Guarize J, et al. Lung cancer surgery in oligometastatic patients: outcome and survival. Eur J Cardiothorac Surg. 2020;57:1173–80.

    Article  Google Scholar 

  5. Suzawa K, Soh J, Takahashi Y, Sato H, Shien K, Yamamoto H, et al. Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy. Surg Today. 2019;49:601–9.

    Article  Google Scholar 

  6. The Japan Lung Cancer Society, Guideline 2019 Edition Committee. Lung cancer practice guidelines 2019 edition. https://www.haigan.gr.jp/guideline/2019/1/2/190102040100.html. Accessed Apr 2020.

  7. Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep. 2002;4:317–24.

    Article  Google Scholar 

  8. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10:113–29.

    Article  CAS  Google Scholar 

  9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

    Article  CAS  Google Scholar 

  10. Broderick SR. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin. 2020;30:215–20.

    Article  Google Scholar 

  11. Stewart LA, Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909.

    Article  Google Scholar 

  12. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–77.

    Article  Google Scholar 

  13. Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, et al. Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38:2187–96.

    Article  CAS  Google Scholar 

  14. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–21.

    Article  CAS  Google Scholar 

  15. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23:4999–5006.

    Article  CAS  Google Scholar 

  16. Toyooka S, Okumura N, Nakamura H, Nakata M, Yamashita M, Tada H, et al. A multicenter randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer. J Thorac Oncol. 2018;13(5):699–706. https://doi.org/10.1016/j.jtho.2018.02.015.

    Article  PubMed  Google Scholar 

  17. Soh J, Okumura N, Nakata M, Nakamura H, Fukuda M, Kataoka M, et al. Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. Jpn J Clin Oncol. 2016;46:741–7.

    Article  Google Scholar 

  18. Kunitoh H, Tsuboi M, Wakabayashi M, Okada MA, Suzuki K, Watanabe S, et al. A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707). JTCVS Open. 2020. https://doi.org/10.1016/j.xjon.2020.08.009.

    Article  Google Scholar 

  19. Okumura N, Sonobe M, Okabe K, Nakamura H, Kataoka M, Yamashita M, et al. Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001. Int J Clin Oncol. 2017;22:274–82.

    Article  CAS  Google Scholar 

  20. Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer: results of a West Japan Oncology Group study. J Clin Oncol. 2010;28:5240–6.

    Article  CAS  Google Scholar 

  21. Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs. 2005;16:1123–8.

    Article  CAS  Google Scholar 

  22. Kelly K, Altorki NK, Eberhardt WE, O’Brien ME, Spigel DR, Crinò L, et al. Adjuvant erlotinib versus PBO in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–14.

    Article  CAS  Google Scholar 

  23. Goss GD, O’Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, et al. Gefitinib versus PBO in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31:3320–6.

    Article  CAS  Google Scholar 

  24. Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, et al. SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer version 2. J Clin Oncol. 2019;37:97–104.

    Article  CAS  Google Scholar 

  25. Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19:139–48.

    Article  CAS  Google Scholar 

  26. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer. Lancet. 2009;374:379–86. https://doi.org/10.1016/S0140-6736(09)60737-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sears CR, Cooney SA, Chin-Sinex H, Mendonca MS, Turchi JJ. DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. DNA Repair (Amst). 2016;40:35–46. https://doi.org/10.1016/j.dnarep.2016.02.004.

    Article  CAS  Google Scholar 

  28. Toyooka S, Kiura K, Shien K, Katsui K, Hotta K, Kanazawa S, et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;15:954–60.

    Article  Google Scholar 

  29. Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer. 2012;118(24):6126–35. https://doi.org/10.1002/cncr.26689.

    Article  CAS  PubMed  Google Scholar 

  30. Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386:1049–56.

    Article  Google Scholar 

  31. Toyooka S, Soh J, Yamamoto H, Yamane M, Hattori S, Shien K, Miyoshi K, et al. Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer. Surg Today. 2015;45:1121–6.

    Article  CAS  Google Scholar 

  32. Sato H, Toyooka S, Soh J, Hotta K, Katsui K, Shien K, et al. Advantage of induction chemoradiotherapy for lung cancer in securing cancer-free bronchial margin. Ann Thorac Surg. 2017;104:971–8.

    Article  Google Scholar 

  33. Sugimoto S, Soh J, Suzawa K, Miyoshi K, Otani S, Yamamoto H, et al. Pulmonary aspergillosis as a late complication after surgery for locally advanced non-small cell lung cancer treated with induction chemoradiotherapy. Surg Today. 2020;50(8):863–71.

    Article  CAS  Google Scholar 

  34. Soh J, Sugimoto S, Namba K, Miura A, Shiotani T, Yamamoto H, et al. Chronic lung injury after trimodality therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg. 2020. https://doi.org/10.1016/j.athoracsur.2020.07.068.

    Article  PubMed  Google Scholar 

  35. Torigoe H, Soh J, Tomida S, Namba K, Sato H, Katsui K, et al. Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. J Thorac Dis. 2017;9:3076–86.

    Article  Google Scholar 

  36. Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33:4194–201.

    Article  CAS  Google Scholar 

  37. Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Swiss Group for Clinical Cancer Research (SAKK), et al. Multimodal treatment in operable stage III NSCLC: a pooled analysis on long-term results of three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol. 2019;14(1):115–23. https://doi.org/10.1016/j.jtho.2018.09.011.

    Article  CAS  PubMed  Google Scholar 

  38. Dall’Olio FG, Conci N, Rossi G, Fiorentino M, De Giglio A, Grilli G, et al. Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients—a single centre experience. Lung Cancer. 2020;149:5–9. https://doi.org/10.1016/j.lungcan.2020.08.008 (Online ahead of print).

    Article  PubMed  Google Scholar 

  39. Yang CJ, McSherry F, Mayne NR, Wang X, Berry MF, Tong B, et al. Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer. Ann Thorac Surg. 2018;105:924–9.

    Article  Google Scholar 

  40. Eichhorn F, Klotz LV, Bischoff H, Thomas M, Lasitschka F, Winter H, et al. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. BMC Cancer. 2019;19(1):413. https://doi.org/10.1186/s12885-019-5624-2.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Dickhoff C, Senan S, Schneiders FL, Veltman J, Hashemi S, Daniels JMA, et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3–4N0-1 non-small cell lung cancer: the INCREASE trial. BMC Cancer. 2020;20(1):764. https://doi.org/10.1186/s12885-020-07263-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ahern E, Cubitt A, Ballard E, Teng MWL, Dougall WC, Smyth MJ, et al. Pharmacodynamics of pre-operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials. 2019;20(1):753. https://doi.org/10.1186/s13063-019-3951-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Reuss JE, Anagnostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020;8(2):e001282. https://doi.org/10.1136/jitc-2020-001282.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Tfayli A, Al Assaad M, Fakhri G, Akel R, Atwi H, Ghanem H, et al. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. Cancer Med. 2020. https://doi.org/10.1002/cam4.3456.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–86.

    Article  CAS  Google Scholar 

  46. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, RECIST working group, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52. https://doi.org/10.1016/S1470-2045(17)30074-8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, et al. A pilot study of atezolizumab plus hypofractionated image-guided radiation therapy for the treatment of advanced non-small cell lung cancer [published online ahead of print 2019 Nov 19]. Int J Radiat Oncol Biol Phys. 2019. https://doi.org/10.1016/j.ijrobp.2019.10.047.

    Article  PubMed  Google Scholar 

  48. Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2020;108(1):212–24. https://doi.org/10.1016/j.ijrobp.2020.05.002.

    Article  PubMed  Google Scholar 

  49. Campbell JD, Lathan C, Sholl L, Ducar M, Vega M, Sunkavalli A, et al. Comparison of prevalence and types of mutations in lung cancers among black and white populations. JAMA Oncol. 2017;3:801–9. https://doi.org/10.1001/jamaoncol.201.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Qian J, Nie W, Lu J, Zhang L, Zhang Y, Zhang B, et al. Racial differences in characteristics and prognoses between asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. Int J Cancer. 2020;146:3124–33. https://doi.org/10.1002/ijc.32717 (Epub 2019 Nov 1).

    Article  CAS  PubMed  Google Scholar 

  51. Zheng R, Shen Q, Mardekian S, Solomides C, Wang ZX, Evans NR 3rd. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020;160:e71–9. https://doi.org/10.1016/j.jtcvs.2019.11.126 (Epub 2019 Dec 20).

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

We declare that we received no funding associated with this manuscript.

Author information

Authors and Affiliations

  1. Departments of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Kita-ku, Okayama City, Okayama, 700-8558, Japan

    Masaomi Yamane & Shinichi Toyooka

Authors
  1. Masaomi Yamane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinichi Toyooka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaomi Yamane.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamane, M., Toyooka, S. Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives. Surg Today 52, 1–11 (2022). https://doi.org/10.1007/s00595-021-02228-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-021-02228-2

Keywords

Search

Navigation